Señales en vivo de 003000.KS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 02:30):

Stats
Volumen de hoy	94 833.00
Volumen promedio	689 294
Capitalización de mercado	408.25B
EPS	KRW0 ( 2024-04-22 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.24 (0.12%)

Volumen Correlación

Largo: -0.02 (neutral)

Corto: -0.54 (weak negative)

Signal:(46.978) Neutral

Bukwang Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bukwang Pharmaceutical Correlación - Moneda/Commodity

0.58
( weak )

0.03
( neutral )

-0.30
( neutral )

0.06
( neutral )

0.41
( neutral )

0.43
( neutral )

Bukwang Pharmaceutical Finanzas

Annual	2023
Ingresos:	KRW125.93B
Beneficio Bruto:	KRW50.05B (39.74 %)
EPS:	KRW-457.67

FY	2023
Ingresos:	KRW125.93B
Beneficio Bruto:	KRW50.05B (39.74 %)
EPS:	KRW-457.67

FY	2022
Ingresos:	KRW190.91B
Beneficio Bruto:	KRW79.43B (41.61 %)
EPS:	KRW-62.07

FY	2021
Ingresos:	KRW182.49B
Beneficio Bruto:	KRW75.76B (41.51 %)
EPS:	KRW-8.74

Financial Reports:

No articles found.

Bukwang Pharmaceutical

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.